Piromelatine

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319700

CAS#: 946846-83-9

Description: Piromelatine, also known as NEU-P11, is a multimodal sleep drug under development by Neurim Pharmaceuticals. It is an agonist at melatonin MT1/MT2 and serotonin 5-HT1A/5-HT1D receptors. Pre-clinical studies showed antinociceptive, antihypertensive and cognitive benefits in rat disease models of pain, hypertension, and Alzheimer's disease.

Chemical Structure

Piromelatine

CAS# 946846-83-9

Instruction

Theoretical Analysis

MedKoo Cat#: 319700
Name: Piromelatine
CAS#: 946846-83-9
Chemical Formula: C17H16N2O4
Exact Mass: 312.11
Molecular Weight: 312.325
Elemental Analysis: C, 65.38; H, 5.16; N, 8.97; O, 20.49

Price and Availability

Size	Price	Availability	Quantity
1g	USD -1
2g	USD -1
5g	USD -1
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: NEU-P11; NEU-P 11; NEU-P-11; Piromelatine

IUPAC/Chemical Name: N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-oxo-4H-pyran-2-carboxamide

InChi Key: PNTNBIHOAPJYDB-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H16N2O4/c1-22-13-2-3-15-14(9-13)11(10-19-15)4-6-18-17(21)16-8-12(20)5-7-23-16/h2-3,5,7-10,19H,4,6H2,1H3,(H,18,21)

SMILES Code: O=C(C1=CC(C=CO1)=O)NCCC2=CNC3=C2C=C(OC)C=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 312.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Zisapel N. Current Phase II investigational therapies for insomnia. Expert Opin Investig Drugs. 2015 Mar;24(3):401-11. doi: 10.1517/13543784.2015.987340. Epub 2014 Nov 25. Review. PubMed PMID: 25423562.

2: Hardeland R. Melatonin and Synthetic Melatoninergic Agonists in Psychiatric and Age-associated Disorders: Successful and Unsuccessful Approaches. Curr Pharm Des. 2015 Dec 14. [Epub ahead of print] PubMed PMID: 25248806.

3: Yu J, Wei J, Ji L, Hong X. Exploration on mechanism of a new type of melatonin receptor agonist Neu-p11 in hypoxia-reoxygenation injury of myocardial cells. Cell Biochem Biophys. 2014 Nov;70(2):999-1003. doi: 10.1007/s12013-014-0009-2. PubMed PMID: 24840226.

4: Liu YY, Yin D, Chen L, Qu WM, Chen CR, Laudon M, Cheng NN, Urade Y, Huang ZL. Piromelatine exerts antinociceptive effect via melatonin, opioid, and 5HT1A receptors and hypnotic effect via melatonin receptors in a mouse model of neuropathic pain. Psychopharmacology (Berl). 2014 Oct;231(20):3973-85. doi: 10.1007/s00213-014-3530-5. Epub 2014 Apr 4. PubMed PMID: 24700387.

5: Chen C, Fichna J, Laudon M, Storr M. Antinociceptive effects of novel melatonin receptor agonists in mouse models of abdominal pain. World J Gastroenterol. 2014 Feb 7;20(5):1298-304. doi: 10.3748/wjg.v20.i5.1298. PubMed PMID: 24574803; PubMed Central PMCID: PMC3921511.

6: She M, Hu X, Su Z, Zhang C, Yang S, Ding L, Laudon M, Yin W. Piromelatine, a novel melatonin receptor agonist, stabilizes metabolic profiles and ameliorates insulin resistance in chronic sleep restricted rats. Eur J Pharmacol. 2014 Mar 15;727:60-5. doi: 10.1016/j.ejphar.2014.01.037. Epub 2014 Jan 30. PubMed PMID: 24486392.

7: Huang L, Zhang C, Hou Y, Laudon M, She M, Yang S, Ding L, Wang H, Wang Z, He P, Yin W. Blood pressure reducing effects of piromelatine and melatonin in spontaneously hypertensive rats. Eur Rev Med Pharmacol Sci. 2013 Sep;17(18):2449-56. PubMed PMID: 24089222.

8: Li X, Cai S, Yin W, Hu X. Neu-p11 reduces clock/apelin expression in insulin-resistant mouse adipocyte model. Acta Biochim Biophys Sin (Shanghai). 2013 Sep;45(9):798-800. doi: 10.1093/abbs/gmt077. PubMed PMID: 23963596.

9: Wang PP, She MH, He PP, Chen WJ, Laudon M, Xu XX, Yin WD. Piromelatine decreases triglyceride accumulation in insulin resistant 3T3-L1 adipocytes: role of ATGL and HSL. Biochimie. 2013 Aug;95(8):1650-4. doi: 10.1016/j.biochi.2013.05.005. Epub 2013 May 23. PubMed PMID: 23707538.

10: He P, Ouyang X, Zhou S, Yin W, Tang C, Laudon M, Tian S. A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease. Horm Behav. 2013 Jun;64(1):1-7. doi: 10.1016/j.yhbeh.2013.04.009. Epub 2013 May 4. PubMed PMID: 23651610.

11: Oertel R, Goltz L, Kirch W. Elucidation of Neu-P11 metabolism in urine of volunteers by liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2013 Feb 22;1278:69-75. doi: 10.1016/j.chroma.2012.12.063. Epub 2013 Jan 8. PubMed PMID: 23336948.

12: Oertel R, Goltz L, Kirch W. Determination of the novel melatonin agonist Neu-P11 in plasma samples by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2013 Feb 23;74:66-70. doi: 10.1016/j.jpba.2012.09.020. Epub 2012 Oct 27. PubMed PMID: 23245235.

13: Paulis L, Simko F, Laudon M. Cardiovascular effects of melatonin receptor agonists. Expert Opin Investig Drugs. 2012 Nov;21(11):1661-78. doi: 10.1517/13543784.2012.714771. Epub 2012 Aug 23. Review. PubMed PMID: 22916799.

Your view history